Since 2001, the Hexacath clinical programme has enrolled thousands of patients internationally and has established the proven efficacy and safety of the Titanium Nitride Oxide coated stents in various population subsets such as Acute Coronary Syndrome patients, small vessels or diabetics. Randomized studies have demonstrated the superiority of this technology versus the first generation DES and its non inferiority versus the most recent DES generations with a trend towards higher safety as soon as 18 months after implantation. At last, Titanium Nitride Oxide Bio Active Stents require only a short term dual anti platelet treatment post stenting.
International Journal of Cardiology
Long-term clinical outcome of titanium-nitride-oxide-coated stents ver...
Novel monorail infusion catheter for volumetric coronary blood flow me...
Annals of Medicine
Stent-oriented versus patient-oriented outcome in patients undergoing ...
Neointimal coverage and vasodilator response to titanium-nitride-oxide...
Outcome of ST-elevation myocardial infarction versus non-ST-elevation ...